The BioHub - by Avetix

We welcomed Mandana Honu onto the BioHub podcast

In this episode of The BioHub Podcast, Ben is joined by Dr. Marc Hedrick, President & CEO of Cerenome, and Russell Bradley, President & General Manager of CNSide Diagnostics.
We explore why CNS cancers remain so difficult to diagnose and treat, and how Cerenome is attempting to address both sides of that problem.
Russell takes us inside CNSide®, the company’s cerebrospinal fluid-based diagnostic platform, including how it differs from traditional cytology, the importance of rare-cell characterisation, and what better diagnostic information could mean for treatment decisions.
Marc then discusses REYOBIQ™, Cerenome’s targeted radiotherapeutic platform, the challenge of delivering sufficient therapeutic intensity into the CNS while managing toxicity, and the broader opportunity to connect diagnosis, treatment and longitudinal monitoring.
A fascinating conversation at the intersection of diagnostics, therapeutics and precision CNS oncology.

In this episode of The BioHub by Avetix, I’m joined by Dan O’Connell, President and CEO of Acumen Pharmaceuticals.

Dan shares his journey from neuroscience investing and company creation into the CEO role, and how he has helped take Acumen from a private, preclinical biotech into a publicly traded clinical-stage company focused on Alzheimer’s disease.

We discuss the origins of Acumen, what it was like taking the company public with just nine people, navigating a difficult few years for biotech, balancing financial discipline with clinical progress, and the major readout ahead later this year.

In this episode of The BioHub by Avetix, I’m joined by Paul Hastings, CEO of Nkarta.

Paul has spent more than three decades in biotech, leading companies across oncology, rare disease and cell therapy, while also becoming one of the industry’s most prominent patient advocates. At Nkarta, he’s now leading the development of allogeneic NK cell therapies designed to make cell therapy safer, more scalable and more accessible.

We discuss the evolution of biotech since Paul entered the industry in 1989, the future of cell therapy, the challenges of scaling access, the US clinical and regulatory environment, the importance of patient advocacy, and the mentors and lessons that have shaped his career.

We welcomed Lei Fang the CEO of Excalipoint to the BioHub